Table 2.

bFGF, FGFR1, and FGFR2 immunohistochemical expression in NSCLC types by histology, sex, and smoking status

No.Immunohistochemical markers, mean (SD)
bFGF

FGFR1

FGFR2

Cytoplasmic expression score*Nuclear expression scoreCytoplasmic expression score*Nuclear expression scoreCytoplasmic expression score*Nuclear expression score
Adenocarcinoma
    Sex
        Male74169.6 (47.6)8.1 (9.4)196.1 (27.7)25.1 (18.9)151.4 (37.4)32.4 (23.1)
        Female122166.1 (46.3)11.9 (12.7)194.6 (28.6)31.8 (19.7)151.9 (35.0)33.9 (23.0)
        P0.620.030.730.020.920.65
    Smoking status
        Never50162.5 (45.0)11.6 (9.6)184.7 (24.2)38.4 (17.6)148.4 (33.6)41.5 (24.1)
        Ever146169.1 (47.3)10.1 (12.3)198.8 (28.6)26.2 (19.4)152.9 (36.6)30.5 (22.1)
        P0.400.440.0020.00010.450.003
SCC
    Sex
        Male79174.5 (33.1)12.9 (13.2)193.3 (24.9)18.3 (14.2)166.1 (36.0)24.2 (17.3)
        Female46164.3 (37.0)15.1 (12.8)189.1 (26.5)19.0 (13.5)160.9 (36.6)26.9 (18.8)
        P0.120.360.360.800.440.43
    Smoking status
        Never6176.7 (46.3)5.8 (13.3)185.0 (15.2)17.5 (11.7)141.7 (43.1)12.3 (9.9)
        Ever118170.2 (35.1)14.1 (13.2)192.3 (25.5)18.5 (14.1)165.6 (35.6)25.8 (18.0)
        P0.660.130.480.860.110.07
  • * Cytoplasmic immunostaining expression was quantified using a four-value intensity score (0, 1+, 2+, and 3+) and the percentage (0-100%) of the extent of reactivity. The cytoplasmic expression score was obtained by multiplying both intensity and reactivity extension values (range, 0-300).

  • Nuclear immunostaining expression was quantified using a range of 0 to 100 according to the percentage of positive nuclei.